You are here

Articles

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With CML

Posted on Tuesday, November 15, 2016 - 11:48am
 
Read more

Closer to a Cure? Researchers at centres in the US and Scotland have discovered ways to target Leukaemic Stem Cells (LSCs).

Posted on Saturday, September 17, 2016 - 11:32am
Researchers at centres in the US and Scotland have discovered ways to target the Leukaemic Stem Cell (LCSs).
Read more

Webcast link for the CML Patient Day 2016 - Saturday, 24th September

Posted on Friday, September 16, 2016 - 9:31pm
http://www.mpdmeetings.org/patient-conference-2016/
Read more

ABL001 for Treating CML: Timothy P. Hughes, MD

Posted on Saturday, September 10, 2016 - 3:44pm
ABL001 is a small molecule inhibitor of BCR-ABL, which is the same protein target of nilotinib and imatinib.
Read more

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

Posted on Wednesday, September 7, 2016 - 9:52pm
Stemming the regrowth of leukemia
Read more

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

Posted on Friday, September 2, 2016 - 2:54pm
 David J Dorer, Ronalk K. Knickerbocker, Michele Baccarani, Jorge E. Cortes, Andreas Hochhaus, Moshe Talpaz, Frank G. Haluska •
Read more

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in CML

Posted on Thursday, August 4, 2016 - 4:56pm
Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome.
Read more

The concept of treatment-free remission in CML

Posted on Thursday, August 4, 2016 - 4:35pm
The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis.
Read more

Dasatinib in imatinib resistant or intolerant chronic phase Chronic Myeloid Leukaemia patients: 7-year follow-up of study CA180-034

Posted on Monday, July 18, 2016 - 8:33pm
Neil P. Shah,1* Philippe Rousselot,2 Charles Schiffer,3 Delphine Rea,4 Jorge E. Cortes,5 Jorge Milone,6 Hesham Mohamed,7 Diane Healey,7 Hagop Kantarjian,5 Andreas Hochhaus,8 and Giuseppe Saglio,9
Read more

PegIFN Improves Responses to Dasatinib in Newly Diagnosed CML Patients

Posted on Saturday, May 21, 2016 - 2:12pm
News | May 03, 2016 
Read more

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Posted on Thursday, May 5, 2016 - 3:12pm
A Hochhaus, G Saglio, T P Hughes, R A Larson, D-W Kim, S Issaragrisil, P D le Coutre, G Etienne, P E Dorlhiac-Llacer, R E Clark, I W Flinn, H Nakamae,
Read more

European LeukemiaNet Recommendations for the Management of CML

Posted on Friday, April 15, 2016 - 12:37pm
 
Read more

Mtss1 is a critical epigenetically regulated tumor suppressor in CML

Posted on Wednesday, April 6, 2016 - 3:34pm
Original ArticleLeukemia (2016) 30,  823–832; doi:10.1038/leu.2015.329;published online 19 January 2016
Read more

Dasatinib Commonly Induces Lymphocytosis in CML Patients

Posted on Thursday, March 31, 2016 - 3:35pm
News | March 29, 2016 | Chronic Myeloid Leukaemia, Cancer Complications, Haematologic Malignancies, Leukaemia & LymphomaBy Dave Levitan
Read more

TGF-alpha, IL-6 Levels Predict Responses and Outcomes in CML

Posted on Thursday, March 24, 2016 - 5:20pm
March 22, 2016 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & LymphomaBy Dave Levitan
Read more